MX2022010952A - Compuestos para la degradacion dirigida de brd9. - Google Patents
Compuestos para la degradacion dirigida de brd9.Info
- Publication number
- MX2022010952A MX2022010952A MX2022010952A MX2022010952A MX2022010952A MX 2022010952 A MX2022010952 A MX 2022010952A MX 2022010952 A MX2022010952 A MX 2022010952A MX 2022010952 A MX2022010952 A MX 2022010952A MX 2022010952 A MX2022010952 A MX 2022010952A
- Authority
- MX
- Mexico
- Prior art keywords
- brd9
- compounds
- targeted degradation
- targeted
- degradation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101150052862 brd9 gene Proteins 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102100029893 Bromodomain-containing protein 9 Human genes 0.000 abstract 2
- 101000794032 Homo sapiens Bromodomain-containing protein 9 Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen compuestos para la degradación de la proteína BRD9, o sales farmacéuticamente aceptables de los mismos, para el tratamiento de trastornos mediados por BRD9, que incluyen, sin limitación, proliferación celular anormal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062985774P | 2020-03-05 | 2020-03-05 | |
US202063061659P | 2020-08-05 | 2020-08-05 | |
PCT/US2021/021240 WO2021178920A1 (en) | 2020-03-05 | 2021-03-05 | Compounds for targeted degradation of brd9 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010952A true MX2022010952A (es) | 2022-10-07 |
Family
ID=77612794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010952A MX2022010952A (es) | 2020-03-05 | 2021-03-05 | Compuestos para la degradacion dirigida de brd9. |
Country Status (12)
Country | Link |
---|---|
US (3) | US11691972B2 (es) |
EP (1) | EP4114392A4 (es) |
JP (1) | JP2023516073A (es) |
KR (1) | KR20220166797A (es) |
CN (1) | CN115279370A (es) |
AU (1) | AU2021231898A1 (es) |
BR (1) | BR112022017393A2 (es) |
CA (1) | CA3165309A1 (es) |
IL (1) | IL295709A (es) |
MX (1) | MX2022010952A (es) |
TW (1) | TW202146412A (es) |
WO (1) | WO2021178920A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
JP2021512167A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドFoghorn Therapeutics Inc. | 障害を治療するための方法及び化合物 |
US20230066136A1 (en) | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CN115052594A (zh) | 2020-01-29 | 2022-09-13 | 福宏治疗公司 | 化合物和其用途 |
JP2023516073A (ja) * | 2020-03-05 | 2023-04-17 | シーフォー セラピューティクス, インコーポレイテッド | Brd9の標的分解のための化合物 |
US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
CN115806547A (zh) * | 2021-09-09 | 2023-03-17 | C4医药公司 | 选择的用于brd9的靶向降解的化合物 |
WO2023109892A1 (zh) * | 2021-12-15 | 2023-06-22 | 海思科医药集团股份有限公司 | 一种抑制或降解brd9的化合物及其组合物和药学上的应用 |
WO2023143384A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种抑制或降解hpk1激酶的化合物及其在医药中的用途 |
TW202333695A (zh) * | 2022-01-27 | 2023-09-01 | 大陸商四川海思科製藥有限公司 | 含氮雜芳環化合物及其組合物和藥學上的應用 |
WO2023200800A1 (en) * | 2022-04-11 | 2023-10-19 | Foghorn Therapeutics Inc. | Methods of treating androgen receptor-independent prostate cancer |
WO2023244764A1 (en) * | 2022-06-15 | 2023-12-21 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
WO2023242597A1 (en) | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
WO2024057021A1 (en) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | Compounds for targeted protein degradation |
WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
WO2012078559A2 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
RU2666530C2 (ru) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
JP2016512846A (ja) | 2013-03-13 | 2016-05-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Ras阻害剤およびその使用 |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
WO2015160845A2 (en) | 2014-04-14 | 2015-10-22 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
WO2016065139A1 (en) | 2014-10-24 | 2016-04-28 | Fl Therapeutics Llc | 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin |
JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
EP3265453B1 (en) | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
WO2016149668A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
CN108136044B (zh) | 2015-06-04 | 2021-08-10 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
EP3370715A4 (en) | 2015-11-02 | 2019-05-15 | Yale University | CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US11395820B2 (en) | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
RU2752677C2 (ru) | 2016-04-12 | 2021-07-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка вет |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3455218A4 (en) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
US11285218B2 (en) * | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
CN110062759B (zh) | 2016-09-13 | 2022-05-24 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬 |
EP3858837A1 (en) | 2016-09-13 | 2021-08-04 | The Regents of The University of Michigan | Fused 1,4-diazepines as bet protein degraders |
MX2019007434A (es) | 2016-12-21 | 2019-08-16 | Biotheryx Inc | Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos. |
JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | Egfrタンパク質分解標的化キメラ分子およびその関連する使用方法 |
IL294423B2 (en) | 2016-12-23 | 2024-01-01 | Univ Yale | Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
CN110612294B (zh) | 2017-01-31 | 2024-01-16 | 阿尔维纳斯运营股份有限公司 | 人小脑蛋白配体和包含其的双官能化合物 |
EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION |
WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
EP3728251A1 (en) | 2017-12-18 | 2020-10-28 | F. Hoffmann-La Roche AG | Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety |
JP2021512167A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドFoghorn Therapeutics Inc. | 障害を治療するための方法及び化合物 |
TW201945357A (zh) | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
CN112312904A (zh) | 2018-04-16 | 2021-02-02 | C4医药公司 | 螺环化合物 |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
US20210260171A1 (en) | 2018-06-21 | 2021-08-26 | Foghorn Therapeutics Inc. | Methods of treating disorders |
WO2019246430A1 (en) | 2018-06-21 | 2019-12-26 | Foghorn Therapeutics Inc. | Methods of treating disorders |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
EP3883580A4 (en) | 2018-11-21 | 2023-01-04 | Foghorn Therapeutics Inc. | METHODS OF TREATMENT OF CANCER |
WO2020160196A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
EP3917526A4 (en) | 2019-01-29 | 2022-11-02 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
US20230066136A1 (en) | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
WO2020172655A1 (en) | 2019-02-23 | 2020-08-27 | New York University | Photoswitchable protacs and synthesis and uses thereof |
US20220289711A1 (en) | 2019-07-31 | 2022-09-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
TW202123942A (zh) | 2019-09-16 | 2021-07-01 | 瑞士商諾華公司 | Brd9雙官能基降解劑及其使用方法 |
CN114521196A (zh) | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
US20230072053A1 (en) | 2020-01-29 | 2023-03-09 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
JP2023516073A (ja) * | 2020-03-05 | 2023-04-17 | シーフォー セラピューティクス, インコーポレイテッド | Brd9の標的分解のための化合物 |
-
2021
- 2021-03-05 JP JP2022552714A patent/JP2023516073A/ja active Pending
- 2021-03-05 TW TW110108032A patent/TW202146412A/zh unknown
- 2021-03-05 MX MX2022010952A patent/MX2022010952A/es unknown
- 2021-03-05 CA CA3165309A patent/CA3165309A1/en active Pending
- 2021-03-05 WO PCT/US2021/021240 patent/WO2021178920A1/en unknown
- 2021-03-05 BR BR112022017393A patent/BR112022017393A2/pt not_active Application Discontinuation
- 2021-03-05 IL IL295709A patent/IL295709A/en unknown
- 2021-03-05 CN CN202180019698.XA patent/CN115279370A/zh active Pending
- 2021-03-05 KR KR1020227033975A patent/KR20220166797A/ko active Search and Examination
- 2021-03-05 AU AU2021231898A patent/AU2021231898A1/en active Pending
- 2021-03-05 EP EP21765211.4A patent/EP4114392A4/en active Pending
- 2021-12-02 US US17/541,035 patent/US11691972B2/en active Active
-
2022
- 2022-09-01 US US17/901,775 patent/US20230060334A1/en active Pending
- 2022-10-13 US US17/965,569 patent/US20240051953A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202146412A (zh) | 2021-12-16 |
JP2023516073A (ja) | 2023-04-17 |
IL295709A (en) | 2022-10-01 |
WO2021178920A1 (en) | 2021-09-10 |
US20240051953A1 (en) | 2024-02-15 |
EP4114392A1 (en) | 2023-01-11 |
KR20220166797A (ko) | 2022-12-19 |
AU2021231898A1 (en) | 2022-10-27 |
CN115279370A (zh) | 2022-11-01 |
BR112022017393A2 (pt) | 2022-10-18 |
US20220098194A1 (en) | 2022-03-31 |
CA3165309A1 (en) | 2021-09-10 |
US11691972B2 (en) | 2023-07-04 |
EP4114392A4 (en) | 2024-04-10 |
US20230060334A1 (en) | 2023-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010952A (es) | Compuestos para la degradacion dirigida de brd9. | |
MX2023009185A (es) | Compuestos de benzamida. | |
MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
PH12021551529A1 (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
MX2023001876A (es) | Derivados de rapamicina. | |
PH12020550256A1 (en) | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
MX2021012423A (es) | Métodos y composiciones para degradación de proteínas específicas. | |
PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
MX2019013194A (es) | Procedimientos para preparar compuestos de tipo oxatiazina. | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
CR20220626A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
MX2023004373A (es) | Metodos y composiciones para la degradacion dirigida de proteinas. | |
MX2023008296A (es) | Compuestos de isoindolinona. | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
MX2022007474A (es) | Compuestos macrociclicos. |